From the Journals

Terminal Cancer: What Matters to Patients and Caregivers


 

Managing Unrealistic Expectations

As patients approached the end of life, neither patients nor caregivers shifted their priorities from life extension to symptom management.

This finding raises concerns because it suggests that many patients hold unrealistic expectations regarding their care and “underscores the need for continuous dialogue and reassessment of care goals throughout the progression of illness,” Dr. Ozdemir said.

“This stability in preferences over time suggests that initial care decisions are deeply ingrained or that there may be a lack of ongoing communication about evolving care needs and possibilities as conditions change,” Ozdemir said.

Yet, it can be hard to define what unrealistic expectations mean, said Olivia Seecof, MD, who wasn’t involved in the study.

“I think people are hopeful that a devastating diagnosis won’t lead to the end of their life and that there will be a treatment or something that will change [their prognosis], and they’ll get better,” said Dr. Seecof, palliative care expert with the Supportive Oncology Program at NYU Langone Health’s Perlmutter Cancer Center in New York City.

Giving patients and caregivers a realistic understanding of the prognosis is important, but “there’s more to it than just telling the patient their diagnosis,” she said.

“We have to plan for end of life, what it can look like,” said Dr. Seecof, adding that “often we don’t do a very good job of talking about that early on in an illness course.”

Overall, though, Dr. Seecof stressed that no two patients or situations are the same, and it’s important to understand what’s important in each scenario. End-of-life care requires “an individual approach because every patient is different, even if they have the same diagnosis as someone else,” she said.

This work was supported by funding from the Singapore Millennium Foundation and the Lien Centre for Palliative Care. Dr. Ozdemir and Dr. Seecof had no relevant disclosures.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

FDA Approves New Bladder Cancer Drug
MDedge Hematology and Oncology
Is Osimertinib Better Alone or With Chemotherapy in Non–Small Cell Lung Cancer?
MDedge Hematology and Oncology
Can Rectal Cancer Patients Benefit from Deintensification of Treatment?
MDedge Hematology and Oncology
‘We Need to Rethink Our Options’: Lung Cancer Recurrence
MDedge Hematology and Oncology
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
MDedge Hematology and Oncology
Could Aspirin Help Treat Breast Cancer?
MDedge Hematology and Oncology
Routine Breast Cancer Screening Should Start at Age 40: USPSTF
MDedge Hematology and Oncology
Potential Cure for Early BRCA-Mutated Breast Cancer?
MDedge Hematology and Oncology
The Long, Controversial Search for a ‘Cancer Microbiome’
MDedge Hematology and Oncology
MicroRNAs May Predict Pancreatic Cancer Risk Years Before Diagnosis
MDedge Hematology and Oncology